Skip to content

Assessment of Cardiovascular Risk and Inflammatory Markers in Patients with Rheumatoid Arthritis

Assessment of Oxidative Stress, Cardiovascular Risk Factors and Metabolic Syndrome Frequency in Rheumatoid Arthritis Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-2jvj92
Enrollment
Unknown
Registered
2016-05-05
Start date
2013-03-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

G03.495.710
D09.546.359.448.500
Cross-sectional study in 200 patients with rheumatoid arthritis. Medical consultations were carried out for determination of weight, height, waist circumference, visual analog scale, number of swollen
Other
D12.644.276.374.500.800

Sponsors

Universidade Estadual de Londrina
Lead Sponsor
Fundação Araucária
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with rheumatoid arthritis who meet the criteria of the American College of Rheumatology 2010.

Exclusion criteria

Exclusion criteria: Patients with other autoimmune diseases, kidney, heart, liver, diabetes, acute or chronic infectious diseases; use of metformnas and statins, supplements with antioxidant activity.

Design outcomes

Primary

MeasureTime frame
Patients with rheumatoid arthritis and insulin resistance have increased disease activity as measured by the Disease Activity Score 28 joints (DAS28); inflammatory process at a higher intensity, measured by ESR, C-reactive protein and serum levels of tumor necrosis factor alpha ; and unfavorable redox status assessed by advanced oxidation protein products, plasma total antioxidant capacity when compared to patients with rheumatoid arthritis without insulin resistance.

Secondary

MeasureTime frame
Patients using anti-tumor necrosis factor had lower plasma levels of tumor necrosis factor alpha therapy.;Patients taking anti tumor necrosis factor had higher plasma levels of tumor necrosis factor therapy than those who did not use.

Countries

Brazil

Contacts

Public ContactAndréa Simão

Universidade Estadual de Londrina

deianame@yahoo.com.br+55(43)3371 2321

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 2, 2026